Last Modified: July 2008
Information contained in this section is only current as of the above date. Although we make a good faith effort to update the content of our web site periodically, we do not have a duty to update information contained in our web site, and we will not be liable for any failure to update such information.

Abbott Laboratories
GlaxoSmithKline

See also: R&D Collaborations

Abbott Laboratories
MedImmune entered into an international distribution agreement with Abbott International, an affiliate of Abbott, to distribute Synagis® (palivizumab) and when and if approved, motavizumab (formerly known as Numax®) outside of the United States. Under the terms of the international distribution agreement, the company manufactures and sells Synagis to Abbott at a price based on end-user sales. MedImmune also has certain contractual rights to co-promote motavizumab (when and if approved in the relevant countries) with Abbott International or its affiliates, in certain markets outside the United States.

GlaxoSmithKline
MedImmune and GSK are developing a vaccine against human papillomavirus (“HPV”) to prevent cervical cancer under a strategic alliance. Under the terms of the 1997 agreement, the companies will collaborate on research and development activities. MedImmune conducted Phase 1 and Phase 2 clinical trials and manufactures clinical material for the studies. GSK is responsible for the final development of the product, as well as regulatory, manufacturing, and marketing activities. In exchange for exclusive worldwide rights to MedImmune’s HPV technology, GSK agreed to provide the Company with an up front payment, equity investment and research funding (substantially all received and recognized prior to 2002), as well as potential developmental and sales milestones and royalties on any product sales.

In February 2005, MedImmune amended its agreement with GSK for the development of the HPV vaccine. Under the amended agreement, MedImmune may also receive certain milestone payments and royalties on future development and sales of an investigational HPV vaccine now in Phase 3 development by Merck & Co., Inc (Merck).

In 2000, MedImmune granted a worldwide, exclusive license to its Streptococcus pneumoniae vaccine technology to GSK in exchange for an up front payment and future milestones, plus royalties on any product sales. Under the terms of the agreement, GSK is responsible for all clinical development, manufacturing and sales and marketing activities for the S. pneumoniae vaccine.

MedImmune has rights to a vaccine against certain subunits of Epstein-Barr virus (“EBV”), a herpes virus that is the leading cause of infectious mononucleosis. The vaccine is being developed by GSK under a worldwide collaborative agreement, excluding North Korea and South Korea. Under the agreement, MedImmune could receive future milestone payments, and royalties from GSK based on any net product sales.